Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 8/2019

17.05.2019 | Original Article

Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial

verfasst von: Lucia Zanoni, Alessandro Broccoli, Alessandro Lambertini, Cinzia Pellegrini, Vittorio Stefoni, Filippo Lodi, Cristina Fonti, Cristina Nanni, Pier Luigi Zinzani, Stefano Fanti

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the role of F-18-Fluorothymidine (FLT) PET/CT in lymphoma patients with suspected recurrent or residual disease.

Methods

Adult lymphoma patients presenting with positive or equivocal F-18-FDG PET/CT at end-treatment or follow-up were prospectively addressed to an additional F-18-FLT-PET/CT. SUV max and tumour-to-background ratios (TBRs) were recorded for the most avid lesion. Biopsy or, when not available, clinical or imaging assessment were employed as standard of reference.

Results

Overall 52 patients were recruited. Histology was available in 20/52 patients (38%), proliferation-index (Ki-67) in 14/20. Disease was excluded in 13/52 patients (25%) (one reactive follicular hyperplasia, five reactive-inflammatory tissues, four reactive nodes, two nodal sarcoid-like and one non-specific peri-caecal finding). FDG and FLT scans were concordant in disease restaging in 34/52 patients (65%), whereas in 18/52 cases (35%) relevant discrepancies were recorded. SUV max and TBR were significantly higher in the disease versus the disease-free group, with both tracers (p = 0.0231 and 0.0219 for FDG; p = 0.0008 and 0.0016 for FLT). FLT-SUVmax demonstrated slightly better performance in discriminating benign from malignant lesions (ROC-AUC: 0.8116 and 0.7949 for FLT-SUV max and TBR; 0.7120 and 0.7140 for FDG). Optimal FLT-SUV max cut-offs were searched: three would lead to 95% sensitivity, 81% accuracy, and 39% specificity, whereas seven led to 100%, 41%, and 56% respectively. No statistically significant correlation was observed between the two FLT indices and Ki-67.

Conclusions

According to our results in a clinical setting of recurrent or residual lymphoma, FLT is not significantly superior to FDG and it is unlikely that it will be employed independently. FLT may be restricted to a few specific cases, as complementary to standard FDG imaging, to confirm a diagnosis or to define a better target to biopsy. However, due to FLT suboptimal performance, many findings would remain inconclusive, requiring further diagnostic procedures and reducing the effectiveness of performing an additional FLT scan.
Literatur
1.
Zurück zum Zitat Metser U, Even-Sapir E. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT. Semin Nucl Med. 2007;37:206–22. CrossRefPubMed Metser U, Even-Sapir E. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT. Semin Nucl Med. 2007;37:206–22. CrossRefPubMed
2.
Zurück zum Zitat Rhodes MM, Delbeke D, Whitlock JA, et al. Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma. J Pediatr Hematol Oncol. 2006;28:300–6. CrossRefPubMed Rhodes MM, Delbeke D, Whitlock JA, et al. Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma. J Pediatr Hematol Oncol. 2006;28:300–6. CrossRefPubMed
3.
Zurück zum Zitat Avivi I, Zilberlicht A, Dann EJ, et al. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. Am J Hematol. 2013;88:400–5. CrossRefPubMed Avivi I, Zilberlicht A, Dann EJ, et al. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. Am J Hematol. 2013;88:400–5. CrossRefPubMed
4.
Zurück zum Zitat Han HS, Escalon MP, Hsiao B, et al. High incidence of false- positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituxi-mab-containing regimens. Ann Oncol. 2009;20:309–18. CrossRefPubMed Han HS, Escalon MP, Hsiao B, et al. High incidence of false- positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituxi-mab-containing regimens. Ann Oncol. 2009;20:309–18. CrossRefPubMed
5.
Zurück zum Zitat El-Galaly T, Prakash V, Christiansen I, et al. Efficacy of routine surveillance with positron emission tomography/computed tomography in aggressive non-Hodgkin lymphoma in complete remission: status in a single center. Leuk Lymphoma. 2011;52:597–603. CrossRefPubMed El-Galaly T, Prakash V, Christiansen I, et al. Efficacy of routine surveillance with positron emission tomography/computed tomography in aggressive non-Hodgkin lymphoma in complete remission: status in a single center. Leuk Lymphoma. 2011;52:597–603. CrossRefPubMed
6.
Zurück zum Zitat Zinzani PL, Stefoni V, Tani M, et al. Role of [F-18]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol. 2009;27:1781–7. CrossRefPubMed Zinzani PL, Stefoni V, Tani M, et al. Role of [F-18]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol. 2009;27:1781–7. CrossRefPubMed
7.
Zurück zum Zitat Zinzani PL, Tani M, Trisolini R, et al. Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. Haematologica. 2007;92:771–7. CrossRefPubMed Zinzani PL, Tani M, Trisolini R, et al. Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. Haematologica. 2007;92:771–7. CrossRefPubMed
8.
Zurück zum Zitat Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334–6. CrossRefPubMed Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334–6. CrossRefPubMed
9.
Zurück zum Zitat Aufderklamm S, Todenhöfer T, Gakis G, et al. Thymidine kinase and cancer monitoring. Cancer Lett. 2012;316:6–10. CrossRefPubMed Aufderklamm S, Todenhöfer T, Gakis G, et al. Thymidine kinase and cancer monitoring. Cancer Lett. 2012;316:6–10. CrossRefPubMed
10.
Zurück zum Zitat Toyohara J, Waki A, Takamatsu S, et al. Basis of FLT as a cell proliferation marker: comparative uptake studies with [3H]thymidine and [3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol. 2002;29:281–7. CrossRefPubMed Toyohara J, Waki A, Takamatsu S, et al. Basis of FLT as a cell proliferation marker: comparative uptake studies with [3H]thymidine and [3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol. 2002;29:281–7. CrossRefPubMed
11.
Zurück zum Zitat Rasey JS, Grierson JR, Wiens LW, et al. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43:1210–7. PubMed Rasey JS, Grierson JR, Wiens LW, et al. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43:1210–7. PubMed
12.
Zurück zum Zitat Schwartz JL, Tamura Y, Jordan R, et al. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med. 2003;44:2027–32. PubMed Schwartz JL, Tamura Y, Jordan R, et al. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med. 2003;44:2027–32. PubMed
13.
Zurück zum Zitat Barthel H, Cleij MC, Collingridge DR, et al. 3-Deoxy-3-[18F] fluorothymidine as a new marker for monitoring tumor response to anti- proliferative therapy in vivo with positron emission tomography. Cancer Res. 2003;63:3791–8. PubMed Barthel H, Cleij MC, Collingridge DR, et al. 3-Deoxy-3-[18F] fluorothymidine as a new marker for monitoring tumor response to anti- proliferative therapy in vivo with positron emission tomography. Cancer Res. 2003;63:3791–8. PubMed
14.
Zurück zum Zitat Buck AK, Bommer M, Stilgenbauer S, et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res. 2006;66:11055–61. CrossRefPubMed Buck AK, Bommer M, Stilgenbauer S, et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res. 2006;66:11055–61. CrossRefPubMed
15.
Zurück zum Zitat Soloviev D, Lewis D, Honess D, et al. [18F]FLT: an imaging biomarker of tumour proliferation for assessment of tumour response to treatment. Eur J Cancer. 2012;48:416–24. CrossRefPubMed Soloviev D, Lewis D, Honess D, et al. [18F]FLT: an imaging biomarker of tumour proliferation for assessment of tumour response to treatment. Eur J Cancer. 2012;48:416–24. CrossRefPubMed
16.
Zurück zum Zitat van Waarde A, Elsinga PH. Proliferation markers for the differential diagnosis of tumor and inflammation. Curr Pharm Des. 2008;14:3326–39. CrossRefPubMed van Waarde A, Elsinga PH. Proliferation markers for the differential diagnosis of tumor and inflammation. Curr Pharm Des. 2008;14:3326–39. CrossRefPubMed
17.
Zurück zum Zitat Barwick T, Bencherif B, Mountz JM, et al. Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation. Nucl Med Commun. 2009;30:908–17. CrossRefPubMed Barwick T, Bencherif B, Mountz JM, et al. Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation. Nucl Med Commun. 2009;30:908–17. CrossRefPubMed
18.
Zurück zum Zitat Wang R, Zhu H, Chen Y, et al. Standardized uptake value based evaluation of lymphoma by FDG and FLT PET/CT. Hematol Oncol. 2014;32:126–32. CrossRefPubMed Wang R, Zhu H, Chen Y, et al. Standardized uptake value based evaluation of lymphoma by FDG and FLT PET/CT. Hematol Oncol. 2014;32:126–32. CrossRefPubMed
19.
Zurück zum Zitat Wondergem MJ, Rizvi SNF, Jauw Y, et al. 18F-FDG or 3′-Deoxy-3′- 18F-Fluorothymidine to detect transformation of follicular lymphoma. J Nucl Med. 2015;56:216–21. CrossRefPubMed Wondergem MJ, Rizvi SNF, Jauw Y, et al. 18F-FDG or 3′-Deoxy-3′- 18F-Fluorothymidine to detect transformation of follicular lymphoma. J Nucl Med. 2015;56:216–21. CrossRefPubMed
20.
Zurück zum Zitat Kasper B, Egerer G, Gronkowski M, et al. Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET. Leuk Lymphoma. 2007;48:746–53. CrossRefPubMed Kasper B, Egerer G, Gronkowski M, et al. Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET. Leuk Lymphoma. 2007;48:746–53. CrossRefPubMed
21.
Zurück zum Zitat Herrmann K, Wieder HA, Buck AK, et al. Early response assessment using 3′-deoxy-3′-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res. 2007;13:3552–8. CrossRefPubMed Herrmann K, Wieder HA, Buck AK, et al. Early response assessment using 3′-deoxy-3′-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res. 2007;13:3552–8. CrossRefPubMed
22.
Zurück zum Zitat Mena E, Lindenberg ML, Turkbey BI, et al. A pilot study of the value of 18F-Fluoro-deoxy-thymidine PET/CT in predicting viable lymphoma in residual 18F-FDG avid masses after completion of therapy. Clin Nucl Med. 2014;39:874–81. CrossRefPubMedPubMedCentral Mena E, Lindenberg ML, Turkbey BI, et al. A pilot study of the value of 18F-Fluoro-deoxy-thymidine PET/CT in predicting viable lymphoma in residual 18F-FDG avid masses after completion of therapy. Clin Nucl Med. 2014;39:874–81. CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Herrmann K, Buck AK, Schuster T, et al. Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment. J Nucl Med. 2011;52:690–6. CrossRefPubMed Herrmann K, Buck AK, Schuster T, et al. Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment. J Nucl Med. 2011;52:690–6. CrossRefPubMed
24.
Zurück zum Zitat Herrmann K, Buck AK, Schuster T, et al. A pilot study to evaluate 3′-Deoxy-3'-18F-Fluorothymidine PET for initial and early response imaging in mantle cell lymphoma. J Nucl Med. 2011;52:1898–902. CrossRefPubMed Herrmann K, Buck AK, Schuster T, et al. A pilot study to evaluate 3′-Deoxy-3'-18F-Fluorothymidine PET for initial and early response imaging in mantle cell lymphoma. J Nucl Med. 2011;52:1898–902. CrossRefPubMed
25.
Zurück zum Zitat Boellaard R, Delgado-Bolton R, Oyen WJG, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54. CrossRefPubMed Boellaard R, Delgado-Bolton R, Oyen WJG, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54. CrossRefPubMed
26.
Zurück zum Zitat Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1990;8:1602. CrossRef Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1990;8:1602. CrossRef
27.
Zurück zum Zitat Olweny CL. Cotswolds modification of the Ann Arbor staging system for Hodgkin's disease. J Clin Oncol. 1990;8:1598. CrossRefPubMed Olweny CL. Cotswolds modification of the Ann Arbor staging system for Hodgkin's disease. J Clin Oncol. 1990;8:1598. CrossRefPubMed
28.
Zurück zum Zitat Rayamajhi SJ, Mittal BR, Maturu VN, et al. 18F-FDG and 18F-FLT PET/CT imaging in the characterization of mediastinal lymph nodes. Ann Nucl Med. 2016;30:207–16. CrossRefPubMed Rayamajhi SJ, Mittal BR, Maturu VN, et al. 18F-FDG and 18F-FLT PET/CT imaging in the characterization of mediastinal lymph nodes. Ann Nucl Med. 2016;30:207–16. CrossRefPubMed
29.
Zurück zum Zitat Troost EGC, Vogel WV, Merkx MAW, et al. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med. 2007;48:726–35. CrossRefPubMed Troost EGC, Vogel WV, Merkx MAW, et al. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med. 2007;48:726–35. CrossRefPubMed
30.
Zurück zum Zitat Bollineni VR, Kramer GM, Jansma EP, et al. A systematic review on [18F]FLT-PET uptake as a measure of treatment response in cancer patients. Eur J Cancer. 2016;55:81–97. CrossRefPubMed Bollineni VR, Kramer GM, Jansma EP, et al. A systematic review on [18F]FLT-PET uptake as a measure of treatment response in cancer patients. Eur J Cancer. 2016;55:81–97. CrossRefPubMed
31.
Zurück zum Zitat Schöder H, Zelenetz AD, Hamlin P, et al. Prospective study of 3′-Deoxy-3'-18F-Fluorothymidine PET for early interim response assessment in advanced-stage B-cell lymphoma. J Nucl Med. 2016;57:728–34. CrossRefPubMed Schöder H, Zelenetz AD, Hamlin P, et al. Prospective study of 3′-Deoxy-3'-18F-Fluorothymidine PET for early interim response assessment in advanced-stage B-cell lymphoma. J Nucl Med. 2016;57:728–34. CrossRefPubMed
32.
Zurück zum Zitat Lee H, Kim SK, Kim YI, et al. Early determination of prognosis by interim 3′-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma. J Nucl Med. 2014;55:216–22. CrossRefPubMed Lee H, Kim SK, Kim YI, et al. Early determination of prognosis by interim 3′-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma. J Nucl Med. 2014;55:216–22. CrossRefPubMed
33.
Zurück zum Zitat Minamimoto R, Fayad L, Advani R, et al. Diffuse large B-cell lymphoma: prospective multicenter comparison of early interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST criteria for early therapeutic monitoring. Radiology. 2016;280:220–9. CrossRefPubMedPubMedCentral Minamimoto R, Fayad L, Advani R, et al. Diffuse large B-cell lymphoma: prospective multicenter comparison of early interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST criteria for early therapeutic monitoring. Radiology. 2016;280:220–9. CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Vesselle H, Grierson J, Peterson LM, et al. 18F-Fluorothymidine radiation dosimetry in human PET imaging studies. J Nucl Med. 2003;44:1482–8. PubMed Vesselle H, Grierson J, Peterson LM, et al. 18F-Fluorothymidine radiation dosimetry in human PET imaging studies. J Nucl Med. 2003;44:1482–8. PubMed
35.
Zurück zum Zitat Chalkidou A, Landau DB, Odell EW, et al. Correlation between Ki- 67 immunohistochemistry and 18F-Fluorothymidine uptake in patients with cancer: a systematic review and meta-analysis. Eur J Cancer. 2012;48:3499–513. CrossRefPubMed Chalkidou A, Landau DB, Odell EW, et al. Correlation between Ki- 67 immunohistochemistry and 18F-Fluorothymidine uptake in patients with cancer: a systematic review and meta-analysis. Eur J Cancer. 2012;48:3499–513. CrossRefPubMed
Metadaten
Titel
Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial
verfasst von
Lucia Zanoni
Alessandro Broccoli
Alessandro Lambertini
Cinzia Pellegrini
Vittorio Stefoni
Filippo Lodi
Cristina Fonti
Cristina Nanni
Pier Luigi Zinzani
Stefano Fanti
Publikationsdatum
17.05.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 8/2019
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-019-04323-6

Weitere Artikel der Ausgabe 8/2019

European Journal of Nuclear Medicine and Molecular Imaging 8/2019 Zur Ausgabe